M.D. Anderson Holds First Cancer Meeting in Spanish

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 7
Volume 4
Issue 7

HOUSTON--Spanish-speaking oncologists from around the world stopped off in Houston on their way home from the ASCO meeting to learn more about state-of-the-art cancer care--in their own language.

HOUSTON--Spanish-speaking oncologists from around the world stoppedoff in Houston on their way home from the ASCO meeting to learnmore about state-of-the-art cancer care--in their own language.

The University of Texas M.D. Anderson Cancer Center sponsoredthe 2-day Conferencia Internacional de Oncologist Medica, thefirst ever to be presented exclusively in Spanish at the cancercenter.

"M.D. Anderson is probably the only center in the countrythat could put together such a program in Spanish. At least onephysician or researcher in each of our major services speaks fluentSpanish, and these faculty are on the conference program,"said Dr. Richard Pazdur, assistant vice president of academicaffairs and a conference organizer.

About 5% of M.D. Anderson's patients come from other countriesand most of them speak Spanish. To assist these patients, theCenter has established the International Patient Center, a patientfamily hotel where multilingual staff serve as advocates for patientsfar from home.

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Related Content